Pieris Pharmaceuticals, Inc. (PIRS): Price and Financial Metrics

Pieris Pharmaceuticals, Inc. (PIRS): $0.32

0.01 (-1.84%)

POWR Rating

Component Grades








Add PIRS to Watchlist
Sign Up

Industry: Biotech




#168 of 387

in industry

PIRS Price/Volume Stats

Current price $0.32 52-week high $1.97
Prev. close $0.33 52-week low $0.16
Day low $0.31 Volume 415,600
Day high $0.33 Avg. volume 1,662,504
50-day MA $0.28 Dividend yield N/A
200-day MA $0.85 Market Cap 31.63M

PIRS Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where PIRS ranks best; there it ranks ahead of 86.42% of US stocks.
  • PIRS's strongest trending metric is Value; it's been moving down over the last 90 days.
  • PIRS's current lowest rank is in the Growth metric (where it is better than 6.8% of US stocks).

PIRS Stock Summary

  • Of note is the ratio of PIERIS PHARMACEUTICALS INC's sales and general administrative expense to its total operating expenses; merely 8.75% of US stocks have a lower such ratio.
  • In terms of volatility of its share price, PIRS is more volatile than 95.04% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PIRS comes in at -63.92% -- higher than that of only 8.63% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to PIERIS PHARMACEUTICALS INC, a group of peers worth examining would be SYBX, SPRB, SEEL, STTK, and SYRS.
  • PIRS's SEC filings can be seen here. And to visit PIERIS PHARMACEUTICALS INC's official web site, go to www.pieris.com.

PIRS Valuation Summary

  • In comparison to the median Healthcare stock, PIRS's EV/EBIT ratio is 99.19% lower, now standing at 0.1.
  • PIRS's price/earnings ratio has moved up 6.6 over the prior 106 months.

Below are key valuation metrics over time for PIRS.

Stock Date P/S P/B P/E EV/EBIT
PIRS 2023-09-18 0.9 0.8 -1.2 0.1
PIRS 2023-09-15 0.9 0.8 -1.1 0.1
PIRS 2023-09-14 1.0 0.8 -1.2 0.0
PIRS 2023-09-13 1.0 0.8 -1.2 0.0
PIRS 2023-09-12 1.0 0.8 -1.2 0.0
PIRS 2023-09-11 0.9 0.8 -1.2 0.1

PIRS Growth Metrics

    The year over year net cashflow from operations growth rate now stands at 57.66%.
  • Its 2 year price growth rate is now at -43.71%.
  • Its 5 year revenue growth rate is now at 760.34%.
Over the past 33 months, PIRS's revenue has gone down $17,780,000.

The table below shows PIRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 28.499 -57.943 -34.707
2022-06-30 27.186 -63.649 -41.507
2022-03-31 26.773 -18.165 -46.667
2021-12-31 31.418 -7.66 -45.738
2021-09-30 24.852 -10.133 -50.606
2021-06-30 23.734 -3.219 -48.353

PIRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PIRS has a Quality Grade of C, ranking ahead of 27.39% of graded US stocks.
  • PIRS's asset turnover comes in at 0.193 -- ranking 490th of 561 Business Services stocks.
  • NXTD, ATVI, and AEYE are the stocks whose asset turnover ratios are most correlated with PIRS.

The table below shows PIRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.193 1 -1.697
2021-03-31 0.279 1 -0.852
2020-12-31 0.254 1 -0.693
2020-09-30 0.359 1 -0.373
2020-06-30 0.456 1 -0.199
2020-03-31 0.398 1 -0.367

PIRS Price Target

For more insight on analysts targets of PIRS, see our PIRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.50 Average Broker Recommendation 1.25 (Strong Buy)

Pieris Pharmaceuticals, Inc. (PIRS) Company Bio

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. The company develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is based in Boston, Massachusetts.

PIRS Latest News Stream

Event/Time News Detail
Loading, please wait...

PIRS Latest Social Stream

Loading social stream, please wait...

View Full PIRS Social Stream

Latest PIRS News From Around the Web

Below are the latest news stories about PIERIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PIRS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to close out this week of trading with an overview of the biggest pre-market stock movers to watch Friday morning!

William White on InvestorPlace | August 25, 2023

Is Pieris Pharmaceuticals (PIRS) a Value Trap? A Comprehensive Analysis

Unpacking the Risks and Rewards of Investing in Pieris Pharmaceuticals

Yahoo | August 24, 2023

Pieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's What You Should Know

Pieris Pharmaceuticals (PIRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | August 23, 2023

Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases and cancer, today announced that the Company has achieved an undisclosed milestone payment from Boston Pharmaceuticals.

Yahoo | August 17, 2023

Pieris lays off most staff after AstraZeneca pulls out of partnership

Pieris has also begun the process of exploring strategic alternatives. That could include a merger or acquisition or an asset sale.

Yahoo | July 19, 2023

Read More 'PIRS' Stories Here

PIRS Price Returns

1-mo -25.58%
3-mo 29.55%
6-mo -75.48%
1-year -73.77%
3-year -84.76%
5-year -94.00%
YTD -69.23%
2022 -72.49%
2021 51.20%
2020 -30.94%
2019 36.09%
2018 -64.77%

Continue Researching PIRS

Want to see what other sources are saying about Pieris Pharmaceuticals Inc's financials and stock price? Try the links below:

Pieris Pharmaceuticals Inc (PIRS) Stock Price | Nasdaq
Pieris Pharmaceuticals Inc (PIRS) Stock Quote, History and News - Yahoo Finance
Pieris Pharmaceuticals Inc (PIRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!